There aren’t enough drugs under development to treat antibacterial and antifungal infections in patients with limited treatment options, even though the FDA offers a particular pathway to help expedite such…
After a long night which saw a vote on the Build Back Better Act delayed for many hours, the House of Representatives on Friday morning finally passed the nearly $2…
Citing declining lymphocyte and T-cell counts in some patients, Merck has stopped its phase 2 trial of a dual-agent HIV antiretroviral regimen and is probing similar studies for this concerning…
Within hours of the FDA authorizing booster doses of the Pfizer and Moderna COVID-19 vaccines for all adults, a Centers for Disease Control and Prevention (CDC) expert panel unanimously supported…
The House debated the Build Back Better Act late into the night and was expected to pass the bill, which includes provisions aimed at lowering the price of some prescription…
The Guyer Institute of Molecular Medicine, an Indianapolis, Ind.-based drug compounder, has drawn a warning letter from the FDA for its sterile drug production. Source: Drug Industry Daily
The U.S. government will pay Pfizer $5.29 billion for 10 million treatment courses of its experimental COVID-19 antiviral, Paxlovid (PF-07321332; ritonavir), to be delivered later this year and into 2022.…
AstraZeneca’s one-time dual-antibody injection cut the risk of symptomatic COVID-19 by up to 83 percent and the risk of severe disease by 88 percent in two studies of high-risk patients.…
Novo Nordisk plans to acquire Dicerna Pharmaceuticals for $3.3 billion, a move that will net Novo Nordisk a ribonucleic acid interference (RNAi) platform for identifying genes that can be targeted…
A federal judge has cleared Pfizer’s $345 million settlement resolving claims the drugmaker overcharged for its EpiPen epinephrine self-injector for treatment of severe allergic reactions. Source: Drug Industry Daily